Roche will buy BioMarin without raising extra money

Note: This section contains information in English only.
Source: Bloomberg
© Scanpix/Reuters
Roche Holding AG, a Swiss based health care company, plans to acquire a California-based BioMarin Pharmaceutical Inc., a company, which produces and develops drugs for treating rare diseases and cancer. A possible cost of the deal can reach $15 billion, and Roche will not borrow extra money to pay for BioMarin. On Thursday Roche Holding AG stocks add 0.03% to $65.79 in New York.
Back to articles

Actual Topics

Subscribe to "Fundamental Analysis" feed

Subscribe
Pre viac informácií o Dukascopy Bank CFD / Forex obchodných platformách a ostatných záležitostiach
nás prosím kontaktujte alebo požiadajte o hovor od nás.
For further information regarding potential cooperation,
please call us or make callback request.
To learn more about Dukascopy Bank Binary Options / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
Pre viac informácií o Dukascopy Bank CFD / Forex obchodných platformách a ostatných záležitostiach
nás prosím kontaktujte alebo požiadajte o hovor od nás.
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.